Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Scopio Labs
| Company | Scopio Labs |
|---|---|
| Name of analyzer | X100/X100HT with Full-Field Peripheral Blood Smear Application |
| Contact | Lianne Trantz |
| City, State | Tel Aviv, Israel |
| Website | |
| Analyzer application | diagnostic and research use |
| Dimensions of analyzer (H × W × | 37.5 × 36.2 × 32 in./— |
| Country where analyzer was | Israel/Israel |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2022/— |
| First year analyzer sold outside | 2022/— |
| Foreign locations where company | Canada, U.K., Ireland, Europe, Israel (installed in Canada, U.K., Europe, Israel) |
| Human languages (other than | — |
| Analyzer list price | — (slide maker stainer sold separately) |
| • Analyzer acquisition options | purchase, lease |
| Training included with purchase/Total time for basic training per operator | — |
| • Follow-up training available | yes (extra charge) |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# immature granulocytes, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, %&# reticulocyte count, PLT, RBC, NRBC, WBC |
| Types of testing FDA cleared or approved for analyzer | — |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | — |
| Differential methods used | — |
| Analytical measurement range: • WBC count/RBC count | — |
| Precision: • WBC count/RBC count | — |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | — |
| • Hemoglobin/Platelets | — |
| • Hematocrit/Reticulocytes | — |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | — |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | — |
| Min. specimen volume open mode/Closed mode/Microsample capability | — |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | none/— |
| Analyzer performs delta checks | — |
| Parameters for which flags may appear | customizable to lab procedures and clinical findings (e.g. presence of plasma cells) |
| Analyzer recognizes and holds test results | yes, for potential test rerun (parameters for flags to hold samples defined by vendor) |
| Scattergram display uses cell-specific color | — |
| Histogram display uses color with thresholds | — |
| LIS interface formats supported | HL7 version 2, HL7 version 3 |
| • Middleware interface | yes (can use Remisol, ADM, Data Innovations) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, patient demographics, host query for patient demographics and orders |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes (also provides list of machine codes for each test and corresponding LOINC code) |
| Lab automation system or workcells to which analyzer has a direct interface | available but not operational (to Beckman Coulter) |
| Barcode symbologies read on specimen tube | — |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | — |
| No. of onboard reagents required for standard specimen analysis | — |
| • Reagents ready to use/Reagent tracking method | — |
| Onboard diagnostics for troubleshooting | — |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | — |
| Notes | †also marketed by Beckman Coulter, Siemens Healthineers |